Novel small molecule activators of β-catenin-mediated signaling pathway: structure-activity relationships of indirubins

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 8, 2009, Pages 2282-2284

  Park, Eun Jung ^a   Choi, Soo Jeong ^b   Kim, Yong Chul ^b   Lee, Sang Hyung ^c   Park, Seoung Woo ^d   Lee, Sang Kook ^a  

^a Ewha Womans University   (South Korea)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c Seoul National University   (South Korea)

^d Kangwon National University   (South Korea)

Author keywords

Catenin; 5 Nitro 3 monoxime; Indirubin; Novel activator of Wnt signaling; Wnt signaling

Indexed keywords

6 BROMOINDIRUBIN 3' OXIME; BETA CATENIN; INDIRUBIN; INDIRUBIN 5 NITRO 3' OXIME; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

BETA CATENIN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 63349093079     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.083     Document Type: Article

References (26)

1. Nelson W.J., and Nusse R. Science 303 (2004) 1483 (Review)
2. Harris J.T., and Peifer M. Trends Cell Biol. 15 (2005) 234
3. Jamora C., and Fuchs E. Nat. Cell Biol. 4 (2002) E101
4. Mareel M., Boterberg T., Noe V., Van Hoorde L., Vermeulen S., Bruyneel E., and Bracke M. J. Cell Physiol. 173 (1997) 271
5. Gumbiner B.M. J. Cell Biol. 148 (2000) 399
6. Polakis P. Gene Dev. 14 (2000) 1837
7. Kikuchi A. Biochem. Biophys. Res. Commun. 268 (2000) 243
8. Papkoff J., and Aikawa M. Biochem. Biophys. Res. Commun. 247 (1998) 851
9. Huber O., Korn R., McLaughlin J., Ohsugi M., Herrmann B.G., and Kemler R. Mech. Dev. 59 (1996) 3
10. Helmbrecht K., Kispert A., von Wasielewski R., and Brabant G. Endocrinology 142 (2001) 5261
11. Brennan K.R., and Brown A.M. J. Mammary Gland Biol. Neoplasia. 9 (2004) 119
12. De Ferrari G.V., and Inestrosa N.C. Brain Res. Rev. 33 (2000) 1
13. Mol. Endocrinol. 21 (2007) 2605
14. Gordon M.D., and Nusse R. J. Biol. Chem. 281 (2006) 22429
15. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., and Holder J.C. Chem. Biol. 7 (2000) 793
16. Sato N., Meijer L., Skaltsounis L., Greengard P., and Brivanlou A.H. Nat. Med. 10 (2004) 55
17. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., and Meijer L. Nat. Cell Biol. 1 (1999) 60
18. Marko D., Schätzle S., Friedel A., Genzlinger A., Zankl H., Meijer L., and Eisenbrand G. Br. J. Cancer 84 (2001) 283
19. Moon M.J., Lee S.K., Lee J.W., Song W.K., Kim S.W., Kim J.I., Cho C., Choi S.J., and Kim Y.C. Bioorg. Med. Chem. 14 (2006) 237
20. Grant K.M., Dunion M.H., Yardley V., Skaltsounis A.L., Marko D., Eisenbrand G., Croft S.L., Meijer L., and Mottram J.C. Antimicrob. Agents Chemother. 48 (2004) 3033
21. Knockaert M., Blondel M., Bach S., Leost M., Elbi C., Hager G.L., Nagy S.R., Han D., Denison M., Ffrench M., Ryan X.P., Magiatis P., Polychronopoulos P., Greengard P., Skaltsounis L., and Meijer L. Oncogene 23 (2004) 4400
22. Yost C., Torres M., Miller J.R., Huang E., Kimelman D., and Moon R.T. Genes Dev. 10 (1996) 1443
23. Adachi J., Mori Y., Matsui S., Takigami H., Fujino J., Kitagawa H., Miller III C.A., Kato T., Saeki K., and Matsuda T. J. Biol. Chem. 276 (2001) 31475
24. Xie Y., Liu Y., Ma C., Yuan Z., Wang W., Zhu Z., Gao G., Liu X., Yuan H., Xhen R., Huang S., Wang X., Zhu X., Wang X., Mao Z., and Li M. Neurosci. Lett. 367 (2004) 355
25. TM 2000 reagent (Invitrogen) according to the manufacturer's instructions. Renilla luciferase (pRL-SV40) was transfected as an internal control to normalize the transfection efficiency of each well. After 24 h incubation, the cells were treated with test samples (250 nM) for 24 h. The cells were lysed and performed dual luciferase assay by using the dual luciferase assay kit (Promega) according to the manufacturer's protocol. Results are presented as a relative value calculated by fold increase over control after normalizing ratios of firefly luciferase/renilla luciferase and averaging triplicate samples.
26. ® HRP-chemiluminescent detection kit (Lab Frontier, Seoul, Korea) by LAS-3000 Imager. β-Actin was used as an internal standard.